5 Key Takeaways

• 1

  The FDA approved Pluvicto for adults with PSMA-positive metastatic hormone-sensitive prostate cancer.

• 2

  The approval is based on the phase 3 PSMAddition trial, showing Pluvicto reduced disease progression risk by 28%.

• 3

  An updated analysis indicated a 33% reduction in disease progression or death risk with Pluvicto plus standard care.

• 4

  Grade 3 or higher adverse events occurred in 51% of patients receiving Pluvicto, compared to 43% with standard care.

• 5

  Pluvicto is an intravenous radioligand therapy that targets prostate cancer cells expressing PSMA using lutetium-177.